

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/pjnns>

## Case report

# Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism

Takuya Konno<sup>a</sup>, Owen A. Ross<sup>b</sup>, Robert E. Wharen<sup>c</sup>, Ryan J. Uitti<sup>a</sup>, Zbigniew K. Wszolek<sup>a,\*</sup>

<sup>a</sup>Department of Neurology, Mayo Clinic, Jacksonville, United States

<sup>b</sup>Department of Neuroscience, Mayo Clinic, Jacksonville, United States

<sup>c</sup>Department of Neurosurgery, Mayo Clinic, Jacksonville, United States

## ARTICLE INFO

## Article history:

Received 21 January 2016

Accepted 29 May 2016

Available online 24 June 2016

## Keywords:

Benign tremulous parkinsonism

Parkinson's disease

Deep brain stimulation

Dopamine transporter imaging

Tremor

## ABSTRACT

Benign tremulous parkinsonism (BTP) is characterized by prominent resting tremor combined with action and postural components, and with only subtle rigidity and bradykinesia. This tremor is frequently disabling and poorly responsive to therapy with levodopa. Thus, BTP could be considered either as a distinct clinical disorder or a variant of PD. We present a case of a 57-year-old man who had a 3-year history of severe and functionally disabling resting tremor with action and postural features bilaterally but with left dominant hand predominance. There was only very mild rigidity and bradykinesia and no postural instability. His tremor was refractory to dopaminergic therapy, including carbidopa/levodopa. The dopamine transporter (DAT) imaging showed reduced tracer uptake in the putamen bilaterally, more so on the right side. He was treated with deep brain stimulation (DBS) targeting the right ventral intermediate nucleus of the thalamus. His tremor resolved immediately after procedure. The DAT imaging abnormalities indicate the presynaptic dopamine deficiency. In some autopsied BTP cases classic alpha-synuclein pathology of PD was observed. Thus, despite the lack of levodopa responsiveness BTP likely represents a variant of PD and not a distinct neurodegenerative disorder. DBS should be considered for patients with BTP PD variant despite their poor responsiveness to levodopa treatment.

© 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.

## 1. Introduction

Benign tremulous parkinsonism (BTP) is characterized by severe resting tremor that is usually asymmetric and predominantly affects the upper extremities [1]. Action tremor

with postural and kinetic components is usually present as well. The tremor is often problematic because it is refractory to dopaminergic therapy. Other cardinal parkinsonian signs such as rigidity, bradykinesia, and postural instability are usually mild. These symptoms either do not progress or progress very slowly over the time [1]. It is common for patients with BTP to

\* Corresponding author at: Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States. Tel.: +1 904 953 7229; fax: +1 904 953 6036.

E-mail address: [Wszolek.zbigniew@mayo.edu](mailto:Wszolek.zbigniew@mayo.edu) (Z.K. Wszolek).

<http://dx.doi.org/10.1016/j.pjnns.2016.05.008>

0028-3843/© 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.

have a positive family history of Parkinson's disease (PD) or tremors [1,2]. In some cases BTP can resemble essential tremor (ET) due to significant action and postural features.

Josephs et al. argued that BTP may be a distinct disorder similar to but distinguishable from PD [1]. Others suggest that BTP is a variant of classic PD [3,4]. Here we present a case of BTP with levodopa-refractory resting tremor in which the tremor was completely resolved after deep brain stimulation (DBS).

## 2. Case report

A 57-year-old, left-handed American man presented with a 3-year history of hand tremor. He had severe and persistent resting tremor with postural and kinetic components that affected mostly his left hand (Video 1). He had only mild tremor in his right hand when operating a computer mouse. He was able to cope with basic daily living activities but with significant compromise. Drinking and writing were difficult. His tremor forced him to proceed with earlier retirement from his work as travel agent. He also had mild, bilateral upper extremity rigidity and reduced arm swing, with left side predominance.

His past medical history was unremarkable; in particular he denied a history of head trauma, encephalitis, and exposure to industrial toxins or psychotropic medications. However, his father, two paternal aunts and his maternal grandfather had PD. His father had akinetic-rigid type of PD without any tremor. Additionally, his mother, maternal grandmother, and sister had ET. None of them were examined by us for the independent verification of their diagnosis. Pedigree is depicted in Fig. 1A. He did not carry the most common autosomal dominant PD gene mutation, LRRK2 p.Gly2019Ser.

The results of his brain MRI were normal. Dopamine transporter (DAT) imaging showed reduced tracer uptake in the putamen bilaterally, but the right side displayed less uptake (Fig. 1B). He was treated with various combinations of trihexyphenidyl, pramipexole, amantadine, pramipexole,


propranolol, and carbidopa/levodopa (250 mg three times daily) alone or with entacapone, with very minimal or no benefit.

We diagnosed him as having BTP since his phenotype fulfilled the characteristic features of BTP description except for disease duration; the duration of his illness was only 3 years as opposed to classic descriptions that is usually at least 8 years [1]. Although there were no significant changes to his UPDRS part III score between the worst-off and the best-on (score = 13; documented at his mid-dose state 3 h after the last dose anti-parkinsonian medication), and there was no difference in the Total Tremor Rating Score (25; items 15-21 = 12) with or without anti-parkinsonian medication on two separate examination days prior to surgery, we offered the patient surgical treatment with DBS because his tremor continuously and markedly impeded his daily activities. He was implanted with DBS targeting the right ventral intermediate nucleus of the thalamus. After the procedure his left hand tremor had completely subsided (Video 2). Ten months after DBS, his left-hand tremor did not reemerge, but he still had a slight tremor in his right hand, very mild rigidity, and reduced arm swing predominantly on his left side. There were no adverse events. To cope with these residual symptoms, the patient continued to take the pramipexole and amantadine.

## 3. Discussion

A core feature of BTP is resting hand tremor. Our patient's most prominent symptom was resting tremor, which was substantially more severe than mild action (postural and kinetic) tremor. Although an alternative diagnosis of ET could be considered, the presence of presynaptic neuronal dysfunction as evidenced by his DAT scan, suggests that the underlying etiology is parkinsonism rather than ET. One case series found that 17 out of 26 BTP cases (65%) had reduced striatal tracer uptake on DAT imaging [3] (Table 1). In our case, other mild parkinsonian signs such as asymmetric rigidity and bradykinesia further supported the diagnosis of parkinsonism. In another case series, nearly three quarters (16/21) of the cases that had a clinical diagnosis of BTP were autopsy-proven PD [4]. In addition, some BTP cases have had mutations in PD-associated genes, such as LRRK2 and *parkin* [3-5]. These radiologic, pathological, and genetic observations support the notion that BTP can be a variant of PD. However, BTP cases without Lewy body pathology have also been reported [4,6], suggesting that BTP may be a heterogeneous condition.

Our patient's symptoms were unresponsive to levodopa. In classic PD, tremor is usually very responsive to this therapy. In general, PD patients with poor or no responsiveness to levodopa are considered to be poor candidates for DBS surgery [7]. Nevertheless, we offer our patient a DBS procedure designed to combat his tremor and had an excellent outcome. In one case series of 15 BTP cases treated with DBS, all improved with a long-lasting beneficial effects for the median of 4 years after the procedure [2]. This beneficial response was observed for shorter period (one month to three years) in 3 only cases [1]. However, none of these DBS cases had DAT testing performed. There has been only one reported case of BTP in whom DAT imaging showed bilaterally reduced tracer uptake



**Fig. 1 – Pedigree and dopamine transporter imaging. The proband's father, two paternal aunts, and the proband's maternal grandfather had Parkinson's disease. The proband's mother, maternal grandmother, and sister had essential tremor. Standard pedigree symbols are used; arrow, the proband; circles, female; squares, male; slash through symbols, diseased individuals; ET, essential tremor; PD, Parkinson's disease (A). Dopamine transporter imaging shows decreased tracer uptake in the putamen bilaterally, and this was more prominent on the right side (B).**

**Table 1 – Summary of previous reports of BTP and our case.<sup>a</sup>**

Reference	No. of cases	Family history <sup>b</sup> No. (%)	Refractoriness to levodopa No. (%)	Cases treated with DBS		Cases with DAT imaging		Pathological analysis	Genetic analysis
				No.	Effective: No. (%)	No.	Reduced striatal uptake: No. (%)		
<b>Case series</b>									
1	16	10 (63)	12 (75)	3	3 (100)	NA	NA	NA	NA
2	15	6 (40)	15 (100)	15	15 (100)	NA	NA	NA	NA
3	26	16 (62)	23 (88)	NA	NA	26	17 (65)	NA	LRRK2 mutation (V2390 M) in one case
4	21	5 (24)	15 (71)	NA	NA	NA	NA	PD in 16 cases/ No specific pathology in 5 cases	Parkin mutation in one case
<b>Case reports</b>									
5	1	Yes	No	No	–	Yes	Yes	NA	LRRK2 mutation (G2019S)
6	1	Yes	Yes	No	–	No	–	AD (unrelated)	NA
8	1	No	Yes	Yes	Yes	Yes	Yes	NA	NA
<b>Our case</b>	1	Yes	Yes	Yes	Yes	Yes	Yes	NA	No mutation in LRRK2 (G2019S)

<sup>a</sup> AD = Alzheimer's disease; DAT = dopamine transporter, DBS = deep brain stimulation, NA = not available; PD = Parkinson's disease.

<sup>b</sup> Family history includes tremor and/or Parkinson's disease.

in striatum; this case underwent DBS of the bilateral subthalamic nucleus [8]. Similar to our patient, the tremor in this case resolved after DBS, and a tremor-free state continued for at least one year [8]. None of the pathologically studied BTP cases were treated with DBS.

#### 4. Conclusion

We presented the case whose levodopa-refractory tremor completely resolved after DBS implantation. DBS has a potential to greatly benefit patients who have disabling levodopa-refractory resting tremor. However, the long-term effects of DBS are still unknown. Prospective studies of more BTP cases are needed to investigate the natural disease course, its neuropathological basis, and the long-term effects of DBS on BTP.

#### Conflict of interest

None declared.

#### Acknowledgement and financial support

T. Konno is partially supported by the Uehara Memorial Foundation postdoctoral fellowship and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch. O. Ross is supported by the NIH P50 NS072187, R01 NS078086, Michael J. Fox Foundation, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team, and The Little Family Foundation. R. Wharen receives research funding from Medtronic, St. Jude Medical, and Boston

Scientific. R. Uitti is funded by NIH P50 NS072187, and receives research funding from Medtronic, St. Jude Medical, and Boston Scientific; finally, R Uitti is an associate editor for NEUROLOGY. Z. Wszolek is supported by the NIH P50 NS072187, Mayo Clinic Center for Regenerative Medicine, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team, and The Sol Goldman Charitable Trust.

We would like to thank Ms. Kelly Viola, ELS, for her assistance with the technical preparation of this manuscript

#### Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at [doi:10.1016/j.pjnns.2016.05.008](https://doi.org/10.1016/j.pjnns.2016.05.008).

#### REFERENCES

- [1] Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. *Arch Neurol* 2006;63(3):354–7.
- [2] Savica R, Matsumoto JY, Josephs KA, Ahlskog JE, Stead M, Lee KH, et al. Deep brain stimulation in benign tremulous parkinsonism. *Arch Neurol* 2011;68(8):1033–6.
- [3] Clarimón J, Pagonabarraga J, Paisán-Ruiz C, Campolongo A, Pascual-Sedano B, Martí-Massó JF, et al. Tremor dominant parkinsonism: clinical description and LRRK2 mutation screening. *Mov Disord* 2008;23(4):518–23.
- [4] Selikhova M, Kempster PA, Revesz T, Holton JL, Lees AJ. Neuropathological findings in benign tremulous parkinsonism. *Mov Disord* 2013;28(2):145–52.
- [5] Rizzo G, Marconi S, Capellari S, Scaglione C, Martinelli P. Benign tremulous parkinsonism in a patient with dardarin mutation. *Mov Disord* 2009;24(9):1399–401.

- [6] Rajput AH, Robinson CA, Rajput AH. Benign tremulous parkinsonism: a clinicopathological study. *Mov Disord* 2008;23(2):311-2.
- [7] Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. *Arch Neurol* 2011;68(2):165-71.
- [8] Fukae J, Fukaya C, Oshima H, Ishii K, Tsuboi Y, Katayama Y, et al. Successful treatment with bilateral deep brain stimulation of the subthalamic nucleus for benign tremulous parkinsonism. *Rinsho Shinkeigaku* 2014;54(6):511-4 [Japanese].